Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
268
Cancer hospital Fudan University
Shanghai, Shanghai Municipality, China
RECRUITINGPFS
Time frame: Since the date of random to disease progression or any cause of death,the average time is 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.